Amyloid-β (Aβ) immunotherapy for treatment of Alzheimer’s disease (AD) was first described in 1999 and has been very informative regarding the role of Aβin AD. Through the efforts of many laboratories we now know that it is possible to reduce amyloid burden and many related AD pathologies in numerous animal models of the disease. Furthermore, initial clinical testing with AN1792, composed of Aβ1–42 and an adjuvant, has yielded very important insights into both the clinical potential of the approach and the impact of Aβpeptide on the disease. A brief review of our current understanding of Aβimmunotherapy is described. These findings have led to newer alternative Aβimmunotherapy approaches that include both active and passive approaches that are currently in clinical testing in both the USA and Europe.
|Direct payment||This item at the regular price: USD 38.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50